Publication | Closed Access

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Autoimmune DiseaseMedicineClinical TrialsClinical DermatologyModerate-to-severe Plaque PsoriasisUstekinumab-controlled Phase 3PharmacotherapyDermatologyPsoriatic Arthritis